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Abstract Agmatine, a divalent diamine with two positive
charges at physiological pH, is transported into the matrix
of liver mitochondria by an energy-dependent mechanism,
the driving force of which is the electrical membrane
potential. Its binding to mitochondrial membranes is
studied by applying a thermodynamic treatment of ligand–
receptor interactions on the analyses of Scatchard and Hill.
The presence of two mono-coordinated binding sites S1 and
S2, with a negative influence of S2 on S1, has been dem-
onstrated. The calculated binding energy is characteristic
for weak interactions. S1 exhibits a lower binding capacity
and higher binding affinity both of about two orders of
magnitude than S2. Experiments with idazoxan, a ligand of
the mitochondrial imidazoline receptor I2, demonstrate that
S1 site is localized on this receptor while S2 is localized on
the transport system. S1 would act as a sensor of exogenous
agmatine concentration, thus modulating the transport of
the amine by its binding to S2.
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Abbreviations
ADC Arginine decarboxylase
AGM Agmatine
DW Electrical membrane potential
I2 Imidazoline receptor type two
MAO Monoamine oxidase
MPT Mitochondrial permeability transition
NOS Nitric oxide synthase
PTP Permeability transition pore
RLM Rat liver mitochondria
ROS Reactive oxygen species
Introduction
Agmatine [1-(4-aminobutyl)guanidine] is a biogenic dia-
mine with two positive charges at physiological pH, dis-
covered for the first time by Kossel (1910). This amine,
formed along the polyamines biosynthetic pathway, derives
from arginine decarboxylation, through arginine decar-
boxylase (ADC) activity. For many years this compound
was believed to be present only in plants, bacteria and
invertebrates, since its recent discovery in rat and bovine
brain and then in other mammal organs and cell types. In
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these animals agmatine is both synthesized in situ and
assimilated by external sources, e.g. nutrition, and then
transported into different organs including the liver.
Agmatine exhibits several biological effects: it acts as a
ligand of a-adrenergic and imidazoline I2 receptors, has
neuroprotective and neuromodulating properties and it is
involved in the synaptic signal transduction pathway (Ha-
laris and Plietz 2007). Moreover, agmatine often exhibits
different effects in dependence of the concentration used: it
can act as a nitric oxide synthase (NOS) inhibitor, but also
it can enhance the in vivo nitric oxide synthesis in endo-
thelial cells. It can suppress cell growth, decreasing the
polyamine content (Agostinelli et al. 2010) and activating
the apoptotic process in hepatocytes (Gardini et al. 2001).
In mammalian mitochondria, it behaves as a constitutive
component, being present in the matrix together with its
metabolic enzymes, ADC and agmatinase, and considering
the presence of I2 receptor.
Previous studies, analyzing its interactions with isolated
rat liver mitochondria (RLM), demonstrated a double dose-
dependent effect: in fact, at high concentrations (1 mM) it
exhibits protective properties, acting as a reactive oxygen
species (ROS) scavenger and inhibiting the mitochondrial
permeability transition (MPT), while at low concentrations
(10–100 lM) it exhibits the opposite effects, by inducing
the transition pore (PTP) opening (Battaglia et al. 2007).
In addition, agmatine is transported into the mitochondrial
matrix by a specific energy-dependent mechanism whose
driving force is the membrane potential (DW) (Salvi et al.
2006). This transport system is characterized by different
features depending on the organs (Battaglia et al. 2010).
Thus, there is a strictly relationship between agmatine
and mitochondria, supported by the notorious interaction
between biogenic amines and these organelles (Battaglia
et al. 2007), in which, as stated before, the imidazoline
receptors I2 are constitutively present. These receptors are
60-kDa proteins localized on mitochondrial membranes
and, in particular, by constituting a monoamine oxidase
(MAO) domain. This suggests the receptor involvement in
the enzymatic activity control. In addition, agmatine can
inhibit MAO activity and this effect could reasonably be
mediated by its binding on I2 receptors. (Bousquet 1997;
Head et al. 1998; Toninello et al. 2009).
As above mentioned, a previous study demonstrates the
presence of a specific agmatine transport system on mito-
chondrial membranes (Salvi et al. 2006). This system is
characterized by an electrophoretic behaviour with an
apparent exponential force/flux relationship suggesting the
involvement of a channel. The effect of agmatine binding
on I2 receptor is totally unknown, as well as its physio-
logical role on mitochondria.
In this regard, for better characterizing agmatine inter-
action with mitochondrial membranes and in particular
with I2 receptor, it was applied a thermodynamic treatment
of ligand–receptor interactions (Di Noto et al. 1996, 2002)
with a new computational procedure developed in Prof. Di
Noto’s laboratory.
In this study, by applying the treatment of Scatchard and
Hill, it was found that mitochondrial membranes possess
two agmatine binding sites S1 and S2, both with mono-
coordination. These studies allow delineating a preliminary
hypothesis concerning agmatine binding sites, the first of
which could be identified with the imidazoline receptor I2
while the second one could be the transport site. These
studies were performed in the presence of idazoxan, which
is considered a ligand of I2 receptor.
Materials and methods
Materials
All reagents were purchased from Sigma, except where
indicated, and were of the highest purity commercially
available. [14C]agmatine was prepared as previously
reported (Cabella et al. 2001) and its specific activity was
0.5–0.7 mCi mmol-1.
Isolation of RLM
RLM were isolated by conventional differential centrifu-
gation in a standard medium containing 250 mM sucrose,
5 mM Hepes (pH 7.4) and 1 mM EGTA; EGTA was
omitted from the final washing solution. Protein content
was measured by the biuret method with bovine serum
albumin as a standard.
These studies were performed in accordance with the
guiding principles in the care and use of animals and were
approved by the Italian Ministry of Health.
Standard incubation procedure for RLM
RLM (1 mg prot/ml) were incubated in a water-jacketed
cell at 20C. The standard medium contained 200 mM
sucrose, 10 mM Hepes (pH 7.4), 5 mM succinate, 1.25 lM
rotenone, 1 mM phosphate. Variations and/or other addi-
tions are described with individual experiments presented.
Agmatine uptake and binding analyses
Uptake of [14C]agmatine was determined by a centrifugal
filtration method, as previously described (Toninello et al.
1985).
Binding parameters were obtained by applying ther-
modynamic treatment of ligand–receptor interactions (Di
Noto et al. 1996; Dalla Via et al. 1996; Di Noto et al.
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2002). For the simulation of agmatine binding (B) as a
function of the free agmatine amount in solution (F) it was
applied the following equation, characteristic of a system
with two binding sites:
½B ¼ ½Bmax 1 
½F  1K1;1
1 þ ½FK1;1
0
@
1
Aþ ½Bmax 2 
½F  1K2;1
1 þ ½FK2;1
0
@
1
A ð1Þ
The binding constants and the consequent energies of
interaction were determined using the following Eq. 2 for
Scatchard analyses and Eq. 3 for Hill analyses. The
rationale of these equations, both obtained from the same
general equation (Di Noto et al. 1996, 2002) considers
receptors with different groups of binding sites (s) where
each one could have multiple coordination (ni). The
subsequent algebric elaborations were previously
developed (Dalla Via et al. 1996)
½B
½F ¼
XS
i¼1
½Bmax;i  ½Bi
   1
Ki;1ðtÞ þ eiðFÞ
 
ð2Þ
ln
½B
Bmax;i
  ½B
( )
¼ ln
XS
i¼1
viðFÞ
1
Ki;1ðtÞ þ eiðFÞ
 	( )
þ ln½F
ð3Þ
where
eiðFÞ ¼
Xni
k¼2
½Fk1Qk
j¼1 ki;jðtÞ
represents the appropriate measure of the extent of multiple
coordination on the ith sites. [Bmax,i] is the maximum
concentration of the ith sites that may be bound by the ligand,
[Bi] is the concentration of ith sites bound by the ligand,
[Bmax] is the maximum receptor-bound ligand concentration
and [B] is the concentration bound to the receptor. [F] is the
free ligand concentration, Ki,j(t) is the affinity constant of the
ligand for the ith site, j is the occupancy number, and t is the
time. Equations 4 and 5 were calculated substituting s = 2
and ni = 1 in Eqs. 2 and 3 and by considering t = 0.
½B
½F ¼ ½Bmax  ½Bð Þ 
DK
1 þ b1½F
þ 1
K2;1
 
ð4Þ
where
DK ¼ 1=K1;1

  1=K2;1

 
ln
½B
½Bmax  ½B
 
¼ ln DK
1 þ b1½F
þ 1
K2;1
 
þ ln½F ð5Þ
Fitting was performed through the computational
method described below (see next section).
The distribution of total bound agmatine on its binding
sites was calculated by the parameter Xi(F). This parameter
is the mole fraction of the ith site that may bound in the
receptor and has been calculated by means of Eq. 6:
XiðFÞ ¼ ð½Bmax;i  ½BiÞ=ð½Bmax  ½BÞ
¼ 1=ð1 þ bi½FÞ
ð6Þ
where bi is a parameter that describes the influence of the
parallel filling of the other kth sites in comparison to filling
of the ith site.
The functional dependence of the overall free energy
changes (DG) on the concentration of free agmatine in
solution was calculated from the general Eq. 7:
DG ¼ RT ln BðBmax  BÞ  ½F ð7Þ
These data are fitted satisfactorily using Eq. 8
characteristic for two sites both with mono-coordination:
DG ¼ RTIn DK
1 þ b1½F
þ 1
K2;1
 
ð8Þ
The Hill factor nH(F) has been calculated by means of
Eq. 9:
nHðFÞ ¼ 1 þ
b1 ½F1þb1½F2
h i
DKðtÞ
1
K2;1ðtÞ þ 11þb1½F
h i
DKðtÞ
ð9Þ
characteristic, again, for a system where two binding sites
are present, both with mono-coordination.
Data analyses and fitting methods
Binding parameters and consequent energies were deter-
mined using Eq. 2 for Scatchard and Eq. 3 for Hill anal-
ysis. After that, [Bmax,i], the maximum ith sites
concentrations that may be bound by ligand, were deter-
mined by fitting Eq. 1 on the [B] versus [F] plots. The fits
were performed using a home written package of Igor
procedures working in the Igor Pro ver. 6.0.4.0 of Wa-
veMetrix Inc. (Oregon, USA, 2007). The fits are performed
using the Igor minimization subroutines which are called
from the main package. The distribution of total bound
ligands on their respective binding sites has been deter-
mined by parameter xi(Fi). This parameter was calculated
using Eq. 6. The reported error deviations of determined
parameters were obtained by propagating the experimental
and fitting errors by suitable error propagation formulas.
Results
The results reported in Fig. 1 show the agmatine amount,
in the absence or in the presence of idazoxan, which binds
to mitochondrial membranes at zero time (B), as a function
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of the free amine concentration present in the medium (F).
These data were obtained by extrapolating at zero time the
linear concentration-dependent agmatine uptake by ener-
gized mitochondria, on the y axis of an uptake versus time
diagram (results not reported, an experimental demonstra-
tion is given in Dalla Via et al. 1996). As observable in this
figure the inhibition by idazoxan on agmatine binding
results are evident.
Figures 2 and 3 report agmatine binding analyses using
the thermodynamic treatment of Scatchard and Hill,
respectively. Binding data, showed in Fig. 1, plotted as
dependence of [B]/[F] on [B] (Fig. 2) and ln{[B]/([Bmax]-
[B])} on ln[F] (Fig. 3), were simulated with two series of
curve profiles belonging to Eqs. 2 and 3 present in
‘‘Materials and methods’’, obtained via computer simula-
tions for several range of parameters s (representing the
groups of different binding sites of the receptor) and ni
(their multiple occupancies). The curves that satisfactorily
simulated the experimental data (Figs. 2, 3) are typical for
two binding sites, S1 and S2, both with mono-coordination.
Scatchard analysis gives us information about the receptor
population homogeneity. The obtained function exhibit a
typical hyperbolic trend, indicative for the presence of two
different binding sites with a single coordination (Fig. 2).
The Hill profiles is in accordance with Scatchard repre-
sentation of binding data. Indeed, a linear behaviour is
observed in Fig. 3 which, as expected, deviates slightly
from linearity at low F values.
In Table 1 are reported the agmatine binding parametres
(in the absence or in the presence of idazoxan) obtained
using either the Scatchard or the Hill data representation
method. These data give us some preliminary and quali-
tative information about the type of process examined.
Obviously the fitting of Eqs. 4 and 5 to the Scatchard and
Hill representations gives the same parameters. Indeed, as
expected Eqs. 2 and 3 were derived from an general
equation describing in an unified way the physical–chem-
istry processes of the investigated binding events (Di Noto
Fig. 1 Zero-time bound agmatine, plotted as a function of the free
agmatine concentration. RLM were incubated in standard medium as
indicated in ‘‘Materials and methods’’ in the presence of different
[14C]agmatine concentrations, in the range of 2–2,000 lM (50 lCi/
mmol) and 200 lM idazoxan where indicated. Bound agmatine
values (B) were obtained by extrapolating at zero-time the concen-
tration-dependent agmatine uptake by energized mitochondria. Free
agmatine concentration value (F) was obtained by subtracting B value
from the total agmatine concentration
Fig. 2 Agmatine binding analyses with the thermodynamic treatment
of Scatchard. Experimental data and procedures as in Fig. 1. The
reported lines are the theoretical curves, of which is also reported the
corresponding Eq. 2
Fig. 3 Agmatine binding analyses with the thermodynamic treatment
of Hill. Experimental data and procedures as in Fig. 1. The reported
lines are the theoretical curves, of which is also reported the
corresponding Eq. 3
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et al. 1996, 2002). These analyses demonstrate the presence
of two binding sites on mitochondrial membranes. Con-
cerning agmatine alone, the total binding site concentration
is 120.22 nmol/mg protein distributed between S1 and S2
sites in the percentages of 1 and 99, respectively. The
association constants K1,1 and K2,1 of S1 and S2 sites,
respectively, demonstrate that S1 has a higher affinity than
S2. b1 describes the possible influence of the parallel filling
of S2 on that of S1 site. This parameter, determined by
Eq. 4, results to be very high, indicating that agmatine
binding on S2 can influence its binding on S1. In the
presence of idazoxan it is clear its inhibition on agmatine
binding, which is emphasized by the reduced percentage of
bound agmatine, is of about 0.4%. This effect is not present
on the second site on which idazoxan seems to exhibit an
unexpected effect: the total binding site concentration
(Bmax) and the one referring to the second site (Bmax2) are
increased, although the association constant is reduced.
Moreover, S2 influence on S1 is enhanced (Table 1).
Figure 4 shows the calculation of the molar fraction
ratios X1(F) and X2(F) for the aliquot of free agmatine that
can bind to S1 and S2, respectively. These ratios are also
named ‘‘filling molar fractions’’ (Di Noto et al. 1996,
2002). The values are obtained using parameter b1 reported
in Table 1. These calculations show that, by enhancing the
amount of bound agmatine, X1(F) diminishes and
X2(F) increases. This means that the higher affinity S1 site
is saturated before S2 site.
Figure 5 clearly shows that 1 nmol/mg protein of agm-
atine is sufficient for S1 saturation, while S2 requires higher
amounts of agmatine. In the presence of idazoxan, again,
there is a decrease of agmatine binding to the first site,
while the S2 has even a higher amount of bound agmatine.
The functional dependence of the overall free energy
changes (DG) on the concentration of free agmatine in
solution is showed in Fig. 6. DG have been calculated by
means of the general Eq. 7 and these data are fitted satis-
factorily using Eq. 8, characteristic for two sites both with
mono-coordination. As we can suppose from the previous
data, DG increases in the presence of idazoxan that has an
inhibitory effect on agmatine binding.
In Figure 7 the value of the Hill factor, nH(F), as a
function of the amount of free agmatine bound to mito-
chondrial membrane is reported. This factor has been cal-
culated by means of Eq. 9, characteristic for a system
where two binding sites are present, both with mono-
coordination. nH(F) is nearly 1 for all the concentrations
tested (2.5–2,000 lM). This result indicates that S2 can
significantly influence S1 and the two sites act almost like
one site in the ligand–substrate interactions. In fact, when
this factor is nearly 1, according to the analyses, it means
that there is a system where one site is predominant.
Discussion
As previously demonstrated, the natural occurring poly-
amines are transported into the mitochondrial matrix by a
specific electrophoretic mechanism, depending on DW,
Table 1 Agmatine binding parameters determined by curve fitting of Eqs. 4 and 5 in the data of Scatchard and Hill plots, respectively
Bmax
(nmol/mg prot)
Bmax1
(nmol/mg prot)
Bmax2
(nmol/mg prot)
K1,1
(mg prot/nmol)
K2,1
(mg prot/nmol)
b1
(mg prot/nmol)
AGMATINE 120.22 (3)a 1.34 (4) 118.88 (4) 4.9 (2) 9 10-2 5.2 (4) 9 10-4 93.53 (3)
AGMATINE ? IDAZOXAN 132.09 (4) 0.56 (2) 131.52 (5) 2.3 (3) 9 10-2 3.7 (6) 9 10-4 186.53 (2)
200 lM idazoxan was present in the medium
a Standard deviations in the least significant digits are given in parentheses and were determined by the propagation formula on the basis of
experimental and fitting error analyses
Fig. 4 Molar fraction ratio of agmatine binding. The calculations
refer to the amount of agmatine lacking to fill the binding sites.
X1(F) and X2(F) are the molar fraction ratio to fill the first (S1) and the
second (S2) agmatine binding sites, respectively. Experimental
procedures as in Fig. 1
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with an apparent exponential force/flux relationship (Ton-
inello et al. 1988, 1992a, b).
This transport system has been identified as a protein
channel having two asymmetric energy barriers, with a
binding site, located in the energy well between the two
barriers, responsible for the transport (Toninello et al.
2000). Another binding site for polyamines, having
different functions, was also found (Dalla Via et al. 1996,
1999).
Agmatine that can be considered as another polyamine
is also transported by a similar electrophoretic mechanism,
having several identical properties, but it utilizes a specific
transporter identifiable as a ‘‘single-binding centre-gated
pore’’ (Salvi et al. 2006).
The present study, performed in the aim to further
characterize the above mechanism, confirms, as previously
proposed (Salvi et al. 2006), the presence of two binding
sites on mitochondrial membranes, but it also evidences the
involvement of the imidazoline receptor I2 in this
mechanism.
The presence of two binding sites for agmatine in RLM
is demonstrated in Figs. 2 and 3 showing the analyses of
Scatchard and Hill, respectively, by utilizing the experi-
mental binding data of Fig. 1.
These analyses, performed using a thermodynamic
treatment previously developed (Di Noto et al. 1996,
2002), whose rationale is reported in ‘‘Materials and
methods’’, show that the experimental data of Fig. 1 fit
satisfactorily the theoretical curves typical for two binding
sites, S1 and S2, both with mono-coordination and with
different features.
As a matter of fact, from the parameters presented in
Table 1, agmatine has a major affinity for S1, if compared
with S2, which has a much higher binding capacity
(Bmax1 = 1.34 nmol/mg protein while Bmax2 = 118.88 n-
mol/mg protein).
Since bound agmatine was calculated by zero-time
extrapolation, the evidenced binding sites have to be
located on the outer membrane and/or on the external
Fig. 5 Subdivision of total bound agmatine, B, in two aliquots, B1
and B2, bound to S1 and S2, respectively. Experimental procedures as
in Fig. 1
Fig. 6 Free energy changes in agmatine binding. The points are
obtained by inserting the experimental values of B, F and Bmax in
general Eq. 2. B and F are the same values of Figs. 2 and 3, while
Bmax is 120.22 nmol/mg protein in the absence of idazoxan and
132.09 nmol/mg protein in its presence (see Table 1). The reported
lines are the theoretical curves (see Eq. 8) which fit the experimental
points. The parameters of this equation have been obtained from
Table 1. For DK value see Eq. 5 and Fig. 2. Experimental procedures
as in Fig. 1
Fig. 7 Hill factor [nH(F)] for agmatine binding. B and F, reported in
Eq. 9, are the same as in Figs. 2 and 3. Other parameters are obtained
from Table 1. For DK value see Eq. 5 and Fig. 2. Experimental
procedures as in Fig. 1
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surface of the inner membrane. Also the possibility of
binding to the external side of the gap junctions, that are
the contact sites of the two membranes, has to be consid-
ered, that is where the transporter could be localized to
effectively facilitate agmatine uptake into the mitochon-
drial matrix.
Considering that agmatine is a ligand of the I2 receptor,
the possibility that this receptor could influence agmatine
uptake would represent a significant goal for this investi-
gation. Previous studies, conducted in our lab, demon-
strated that the net amount of transported agmatine, in the
presence of idazoxan, is not altered, while its initial binding
to mitochondrial membranes is significantly modified
(Salvi et al. 2006). The analyses of Figs. 1, 2, 3 have been
performed in the aim to obtain more precise information
about the inhibition of idazoxan, a ligand of I2 receptor, on
the initial agmatine binding observed in the above study.
The results of these analyses (see the binding constants
reported in Table 1) clearly confirm that idazoxan exhibits
an inhibitory effect on agmatine binding, but this inhibition
takes place only at the level of S1 site, while the binding to
S2 increases. The total free energy value, calculated in
Fig. 6, is almost similar as that of the other polyamines
(Dalla Via et al. 1996, 1999) and suggests that agmatine
should bind to mitochondrial sites by conventional weak
interactions. Strongly covalent binding have to be exclu-
ded. The observation that idazoxan significantly increases
this value further confirms its effect.
The thermodynamic model utilized in this study, allows
to obtain other new parameters, to better characterize
agmatine transport: (1) The coordination number of bind-
ing sites. Both sites are mono-coordinated. The binding
data fitted very well with both curves (see Eqs. 5 and 6)
characteristic for mono-coordination. (2) The molar frac-
tion ratio Xi(F) and the consequent evaluation of the two
site filling. As demonstrated by the analyses of Figs. 4 and
5, S1 is filled at low concentrations of ligand, if compared
with S2. (3) b1 value (see Eq. 4). This parameter indicates
the possible effect induced on agmatine binding to S1 site
by agmatine binding to S2 site. In principle b1 values could
range from 0 and infinite. Very high values, as in our case,
indicate the preponderance of S2 site on S1 site in binding
phenomena.
These data are supported also by the Hill factor (see
Fig. 7), which is almost 1 for all the concentrations tested,
demonstrating the predominance of one of the two sites.
The preponderance of S2 site, its high binding capacity and
the lack of a clear saturation (Fig. 1) suggest that S2 site
could be the transport site. This hypothesis is supported
also by the association constant value, lower than the one
referred to S1, which indicates the low affinity of S2 site for
agmatine (Table 1). Thus, this amine is able to dissociate
easily from S2 site, allowing its subsequent transport.
Moreover, the observation that S2 site binds agmatine
before the complete saturation of the first one, supports this
possibility.
As regards S1 site, considering its higher affinity con-
stant in comparison with S2 and idazoxan inhibition on
agmatine binding, it could be identified with the imidazo-
line receptor I2. In addition, from our data, it is possible to
make some observations about the peculiar behaviour of
this ligand. First of all, idazoxan could be considered as an
inhibitor of agmatine binding to S1 site, because its pres-
ence seems to exclude the amine occupancy of this site (as
we can see from the decrease of the binding and affinity
constants for S1 showed in Table 1). This event does not
occur for S2 site, apparently the transport site. As the two
sites are strictly correlated, as evidenced before, it is pos-
sible to formulate the following hypothesis, arising from
the schematic representation of the results of Fig. 8.
The first site, present on imidazoline receptor I2, could
act as a sensor of agmatine concentration in the medium
Fig. 8 Schematic representation of the hypothesis on the function of
different binding sites for agmatine on mitochondrial membranes.
Case 1 refers to a situation/context in which only agmatine (A) is
present in the medium while in Case 2 there is also idazoxan (I).
When only agmatine is present, this amine can bind both to S1 and S2
sites and then be transported into the matrix. The most interesting
case is the second where, if idazoxan binds to S1 site, a lower amount
of agmatine could be detected and then the transport properties of S2
site could be modified, allowing an increased transport of agmatine.
At present, it is not clear if also idazoxan could be transported into the
matrix
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and regulate the second site activity concerning agmatine
transport into the mitochondria. If idazoxan binds to S1
site, agmatine concentration detected is lower and this can
cause a modification of S2 site binding and transport
properties (Case 2). This phenomenon is evidenced by the
increasing binding capacity, allowing S2 site to bind a
major amount of agmatine, and by a decrease of the
association costant, facilitating the amine dissociation from
the binding site and its consequent transport.
These results underline a remarkable difference of
agmatine binding constants from the previous constant
detected for the other polyamines, confirming the dissim-
ilarity between the two transport systems in RLM (Salvi
et al. 2006). The peculiarity of agmatine binding sites
allows us to hypothesize that at least one site can be located
on the imidazoline receptor I2 and can act as a regulator of
the transport function of the other site. Thus, these findings
could delineate a first physiological function of the I2
receptor about which there is not any information at
mitochondrial level. Anyway the peculiar features of
agmatine binding sites and their different behaviours in the
presence of idazoxan suggest that agmatine mitochondrial
transport could be linked to particular pathophysiological
roles of this amine. For example, it is possible that, in vivo,
in liver, the I2 receptor, depending on cytosolic agmatine
concentration, and both the pathophysiological conditions
and the specific functional requirements of the cell, could
address the amine towards MPT induction or prevention.
Experiments are in progress in our laboratory to obtain
further information about agmatine interactions with
mitochondrial membranes and its correlation with the im-
idazoline I2 receptor role on mitochondrial function.
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